Alnylam highlights significant progress with platform innovation and clinical pipeline at r&d day

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, is hosting a virtual r&d day today. during the event, the company plans to showcase its r&d progress and platform innovation, as well as its product and pipeline goals for 2024, including continued commercial execution of four rnai therapeutic products and the advancement of early-, mid-, and late-stage investigational programs. “alnylam continues to drive the next wav.
ALNY Ratings Summary
ALNY Quant Ranking